

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/atm-22-2543	
Item	Question	Authors' Response (place “-” if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The polymorphism data in particular will be shared, and we also found HSP90AA1 rs7160651 and CYP3A5 rs776746 were significantly associated with refractory myasthenia gravis, which has seldom been provided in previous studies.
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Three years within the publication date, since the technique or prognostic data may be updated over time.
7	To whom will you share the data?	Neuroscientists who are interested in studies of myasthenia gravis.
8	For what type of analysis or purpose?	For evaluation of the use of polymorphisms to guide therapy for myasthenia gravis patients.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: bubitao@tjh.tjmu.edu.cn
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.